Key Takeaways
- The government has capped trade margins on non-scheduled anti-cancer drugs at 30% to make cancer treatment more affordable.
- The measure will cover branded and generic drugs, domestically manufactured and imported medicines, and patented and non-patented products.
- The decision is expected to benefit thousands of cancer patients in India who struggle to afford expensive treatments.
What the 30% cap changes for patients
The Union government has decided to cap trade margins at 30% of the maximum retail price (MRP) for all non-scheduled anti-cancer drugs.
This measure aims to make cancer treatment more affordable and reduce patients’ out-of-pocket expenditure.
Around 75% of cancer treatment expenditure is estimated to be borne out of pocket.
Who is affected by the new slab
The measure will cover branded and generic drugs, domestically manufactured and imported medicines, and patented and non-patented products.
An expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines to be brought under the measure.
By the numbers
- 170%: the average trade mark-up on non-scheduled anti-cancer medicines.
- 700%: the mark-up in some cases.
- 225: the number of drugs in the anti-cancer medicines market.
- 500: the number of formulations in the anti-cancer medicines market.
- ₹12,500 crore: the annual turnover of the anti-cancer medicines market.
- ₹2,250 crore: the turnover of scheduled cancer medicines.
- 91%: the price reduction resulting from the 2019 intervention.
- ₹984 crore: the annual savings from the 2019 intervention.
- 70%: the expected price reduction from the latest intervention.
- ₹2,500 crore: the expected annual savings from the latest intervention.
How the government arrived at the decision
The National Pharmaceutical Pricing Authority (NPPA) analysed market data and found substantial differences between prices charged through retail, hospital, and online pharmacies.
The government drew on the experience of a similar intervention in 2019, when the NPPA capped trade margins on 42 selected non-scheduled anti-cancer drugs.
What the new framework entails
Under the new framework, the trade margin will be capped at 30% of MRP, equivalent to 42.86% of the price to stockist.
Manufacturers will be required to maintain their existing production level to ensure availability.
Impact on the distribution chain
The measure will regulate trade margins rather than manufacturers’ selling prices or revenue.
The intervention aims at reducing the margins retained across the distribution chain.
Implications for cancer patients in India
The decision is expected to benefit thousands of cancer patients in India who struggle to afford expensive treatments.
Read also: Habit Forming Drugs: Hyderabad Pharmacies Under Scrutiny
Read also: Affordable Healthcare Expansion
The reduced prices will help decrease the financial burden on patients and their families.
What to watch next
The implementation of the new framework and its impact on the prices of anti-cancer drugs will be closely monitored.
The government’s decision is a significant step towards making cancer treatment more affordable, but its effectiveness will depend on the successful implementation of the new framework.
Challenges ahead
The government will need to ensure that the new framework is implemented effectively and that manufacturers comply with the new regulations.
The impact of the price reduction on the availability of anti-cancer drugs will also need to be monitored.
Expert perspective
Experts in the field have welcomed the government’s decision, saying that it will help make cancer treatment more affordable for patients.
However, some experts have also raised concerns about the potential impact of the price reduction on the availability of anti-cancer drugs.
Frequently Asked Questions
What is the government’s decision on cancer drug prices?
The government has capped trade margins on non-scheduled anti-cancer drugs at 30% to make cancer treatment more affordable.
Who will be affected by the new slab?
The measure will cover branded and generic drugs, domestically manufactured and imported medicines, and patented and non-patented products.
What is the expected impact of the price reduction on cancer patients?
The decision is expected to benefit thousands of cancer patients in India who struggle to afford expensive treatments.
